Quinidine for ventricular arrhythmias: A comprehensive review

• Published in: Trends in cardiovascular medicine 2024-07
• Main Authors: Rakza, Redwane, Groussin, Pierre, Benali, Karim, Behar, Nathalie, Mabo, Philippe, Pavin, Dominique, Leclercq, Christophe, Liang, Jackson J., Martins, Raphaël P.
• Format: Article
• Language: English
• Subjects: Bioengineering; Life Sciences
• ISSN: 1050-1738; 1873-2615; 1873-2615
• DOI: 10.1016/j.tcm.2024.07.003

Quinidine, the first antiarrhythmic drug, was widely used during the 20th century. Multiple studies have been conducted to provide insights into the pharmacokinetics and pleiotropic effects of Class Ia antiarrhythmic drugs. However, safety concerns and the emergence of new drugs led to a decline in their use during the 1990s. Despite this, recent studies have reignited the interest in quinidine, particularly for ventricular arrhythmias, where other antiarrhythmics have failed. In conditions such as Brugada syndrome, idiopathic ventricular fibrillation, early repolarization syndrome, short QT syndrome, and electrical storms, quinidine remains a valuable asset. Starting from the European and American recommendations, this comprehensive review aimed to explore the various indications for quinidine and the studies that support its use. We also discuss the potential future of quinidine, including the necessary research to optimize its use and patient selection. Additionally, it addresses the imperative task of mitigating the iatrogenic burden associated with quinidine usage and confronts the challenge of ensuring drug accessibility.